Trial · NCT07885787
Post Pulmonary Embolism In Patients Treated With Catheter Based Therapy
NCT07885787, Not applicable, Not yet recruiting, Assiut University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post Pulmonary Embolism In Patients Treated With Catheter Based Therapy. Trials, record NCT07885787. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885787
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post Pulmonary Embolism In Patients Treated With Catheter Based Therapy
- NCT number
- NCT07885787
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Assiut University
- Conditions
- Pulmonary Embolism Acute
- Interventions
- The Indigo aspiration system
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effectiveness of mechanical thrombectomy on Post pulmonary embolism functional limitation at 6 months follow up | 6 months | Post-PE functional limitation encompasses new or progressive dyspnea and/or exercise intolerance in the absence of other apparent explanations on diagnostic testing apart from PE assessed by Modified Medical Research Council Dyspnea Scale(mMRC) mMRC Dyspnea Scale which measures the severity of breathlessness during daily activities.Grades are Grade 0 (Breathless only with strenuous exercise) Grade 1 (Short of breath when hurrying on level ground or walking up a slight hill) Grade 2 (Walks slower than people of the same age because of breathlessness, or stops when walking at own pace) Grade 3 (Stops for breath after walking about 100 meters or after a few minutes on level ground) Grade 4 (Too breathless to leave the house, or breathless when dressing or undressing) Interpretation: Higher grade = greater functional limitation. |
| Primary | Effectiveness of mechanical thrombectomy on Post pulmonary embolism cardiac impairment at 6 months follow up | 6 months | Post-PE cardiac impairment is characterized by incomplete RV echocardiographic recovery, as indicated by an intermediate or high echocardiographic probability of pulmonary hypertension (according to the ESC criteria). Criteria for diagnosis post pulmonary embolism impairment include Clinical Criteria Assessed \~6 months after acute PE: Persistent dyspnea (key symptom) Reduced exercise capacity assesed by 6 minutes walk test NYHA functional class ≥ II Unexplained fatigue ± Additional symptoms: Chest discomfort Dizziness / near-syncope Echocardiographic Criteria (Suggestive of PH / CTEPH) 1. Elevated pulmonary pressures 2. Right ventricular (RV) abnormalities 3. RV pressure overload signs 4. Right atrial enlargement 5. Indirect supportive signs: Dilated pulmonary artery |
| Secondary | Occurence of intracranial hemorrhage | at the sooner of discharge or 7 days after the randomization | Intracranial hemorrhage: Any bleeding involving the brain parenchyma, ventricular system, or subarachnoid, subdural, or epidural regions as identified by CT scan or MRI regardless of symptoms. |
| Secondary | Major bleeding according to the ISTH definition in non-surgical subjects | at the sooner of discharge or 7 days after the randomization | Major bleeding according to the ISTH definition in non-surgical subjects includes 1. Fatal bleeding, AND/OR 2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, AND/OR 3. Bleeding causing a fall in hemoglobin level of ≥2 g/dL (1.24 mmol/L) or leading to transfusion of ≥2 units of whole blood or red cells |
| Secondary | Clinical deterioration and escalation to a bailout therapy | at the sooner of discharge or 7 days after the randomization | Clinical deterioration AND/OR escalation to a bailout therapy in a. Clinical deterioration: defined by documented objective hemodynamic or respiratory worsening that is not present at the time of enrollment, including one or more of the following: i. Hypotension with SBP \<90 mmHg lasting at least 30 minutes, unresponsive to fluid resuscitation, and requiring the addition of, or increased dose of, vasopressors. ii. Fall in SBP by ≥40 mmHg lasting at least 30 minutes and accompanied end organ hypoperfusion. iii. Cardiac arrest requiring cardiopulmonary resuscitation. iv. Bradycardia lasting \>10 minutes, accompanied by hypotension and requiring pharmacologic intervention or insertion of a pacemaker. v. Ventricular tachycardia or fibrillation requiring pharmacologic intervention or defibrillation. vi. Requirement for an increase in fraction of inspired oxygen requirements ≥0.20, lasting longer than 30 minutes. vii. Need for intubation in a previously non-intubated patient. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885787
GET https://conductscience.org/api/trials/v1/NCT07885787/registered